Rxsight Stock Performance
| RXST Stock | USD 46.40 0.34 0.74% |
The company holds a Beta of 1.22, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rxsight will likely underperform. At this point, Rxsight has a negative expected return of -0.28%. Please make sure to check Rxsight's maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to decide if Rxsight performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rxsight has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.89 | Five Day Return 3.29 | Year To Date Return 26.79 | Ten Year Return 190.44 | All Time Return 190.44 |
1 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 56.111 subject to Rule 16b-3 | 09/17/2024 |
2 | Disposition of 3105 shares by Ilya Goldshleger of Rxsight at 49.2926 subject to Rule 16b-3 | 09/26/2024 |
3 | Disposition of 206 shares by Ilya Goldshleger of Rxsight at 48.65 subject to Rule 16b-3 | 10/04/2024 |
4 | Disposition of 3105 shares by Ilya Goldshleger of Rxsight at 48.8231 subject to Rule 16b-3 | 10/10/2024 |
5 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.1915 subject to Rule 16b-3 | 10/11/2024 |
6 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.0865 subject to Rule 16b-3 | 10/14/2024 |
7 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.7799 subject to Rule 16b-3 | 10/16/2024 |
8 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 49.6778 subject to Rule 16b-3 | 10/22/2024 |
9 | Disposition of 3100 shares by Ilya Goldshleger of Rxsight at 50.643 subject to Rule 16b-3 | 10/28/2024 |
10 | This little-known medical technology stock can rally more than 40, Jefferies says | 10/29/2024 |
11 | Disposition of 260 shares by Ilya Goldshleger of Rxsight at 51.7372 subject to Rule 16b-3 | 11/04/2024 |
12 | What To Expect From RxSight Inc Q3 2024 Earnings | 11/06/2024 |
13 | RxSight Inc Q3 2024 Earnings Revenue Hits 35.3M, EPS at , Surpassing Estimates | 11/07/2024 |
14 | RxSight Inc Q3 2024 Earnings Call Highlights Robust Revenue Growth and Strategic Market ... | 11/08/2024 |
15 | RxSight Inc Trading Down 3.15 percent on Nov 12 | 11/12/2024 |
16 | Rxsight director Corley makes 1.01m stock purchases | 11/15/2024 |
17 | Disposition of tradable shares by Ilya Goldshleger of Rxsight at 45.07 subject to Rule 16b-3 | 11/18/2024 |
18 | Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. Stock | 11/19/2024 |
19 | RxSight Upgraded to Buy Heres What You Should Know | 11/20/2024 |
| Begin Period Cash Flow | 12.6 M | |
| Free Cash Flow | -46.4 M |
Rxsight |
Rxsight Relative Risk vs. Return Landscape
If you would invest 5,639 in Rxsight on August 30, 2024 and sell it today you would lose (999.00) from holding Rxsight or give up 17.72% of portfolio value over 90 days. Rxsight is currently does not generate positive expected returns and assumes 2.3106% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Rxsight, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rxsight Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rxsight's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rxsight, and traders can use it to determine the average amount a Rxsight's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1222
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RXST |
Estimated Market Risk
| 2.31 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rxsight is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rxsight by adding Rxsight to a well-diversified portfolio.
Rxsight Fundamentals Growth
Rxsight Stock prices reflect investors' perceptions of the future prospects and financial health of Rxsight, and Rxsight fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rxsight Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0992 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 1.63 B | ||||
| Shares Outstanding | 40.3 M | ||||
| Price To Earning | 42.55 X | ||||
| Price To Book | 6.70 X | ||||
| Price To Sales | 14.47 X | ||||
| Revenue | 89.08 M | ||||
| Gross Profit | 21.33 M | ||||
| EBITDA | (41.04 M) | ||||
| Net Income | (48.61 M) | ||||
| Cash And Equivalents | 128.62 M | ||||
| Cash Per Share | 4.65 X | ||||
| Total Debt | 3.01 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 11.54 X | ||||
| Book Value Per Share | 6.89 X | ||||
| Cash Flow From Operations | (41.59 M) | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 1.86 B | ||||
| Total Asset | 182.55 M | ||||
| Retained Earnings | (594.64 M) | ||||
| Working Capital | 147.5 M | ||||
About Rxsight Performance
Assessing Rxsight's fundamental ratios provides investors with valuable insights into Rxsight's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rxsight is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 180.07 | 312.42 | |
| Return On Tangible Assets | (0.27) | (0.25) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.25) | |
| Return On Equity | (0.30) | (0.32) |
Things to note about Rxsight performance evaluation
Checking the ongoing alerts about Rxsight for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rxsight help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rxsight generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 89.08 M. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 21.33 M. | |
| Rxsight currently holds about 128.62 M in cash with (41.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.65. | |
| Rxsight has a strong financial position based on the latest SEC filings | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: RxSight Upgraded to Buy Heres What You Should Know |
- Analyzing Rxsight's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rxsight's stock is overvalued or undervalued compared to its peers.
- Examining Rxsight's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rxsight's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rxsight's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rxsight's stock. These opinions can provide insight into Rxsight's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.